Sat Kartar Life

Sat Kartar Life's board approved a preferential issue of up to 550,000 convertible warrants at Rs 172 each, aggregating Rs 9.46 crore, to three promoter-group allottees, subject to shareholder and regulatory approvals. Each warrant carried a right to subscribe to one equity share of Rs 10 face value within 18 months, with 25% payable on subscription and the balance on conversion, at a price about 18.2% above the Rs 145.51 floor price. Manprit Singh Chadha was to receive 350,000 warrants, Archana Chadha 175,000 and Simrati Kaur 25,000, taking promoter-group holding to 55.52% on full conversion from 54.20%. The board convened an extraordinary general meeting for 23 October 2026, with 16 October as the record date, to seek shareholder approval. The company sold Ayurveda products direct to consumers across 11,600 pincodes from a 30 million-strong consumer database, led by Tamil Nadu, Uttar Pradesh, Karnataka and Andhra Pradesh. Revenue crossed Rs 200 crore in FY26 with EBITDA up 73% and profit up 74%, against revenue of Rs 162.92 crore and profit of Rs 9.82 crore in FY25. Its mix was about 67% specific-problem niche therapeutics including Liv Muztang, Kaama Gold and Addiction Killer and about 33% lifestyle products, with manufacturing outsourced and a capsule factory producing following the Plantomed acquisition.

Powered by Tijori

Sept 15 (Reuters) - Sat Kartar Life Ltd STKA.NS:

• SAT KARTAR LIFE LTD- SIGNED LOI IN CONNECTION WITH PROPOSED ESTABLISHMENT OF 20-BED HOSPITAL-CUM-THERAPY CENTRE IN DEHRADUN

• SAT KARTAR LIFE LTD- ESTIMATED INVESTMENT OF 7 MILLION RUPEES

Source text: [ID:]

Further company coverage: STKA.NS

(([email protected];))

Sat Kartar Life scheduled a group analyst visit to its Sat Kartar Sanjeevan Hospital in Paschim Vihar, Delhi, for September 9, 2026, followed by an interaction with management. Merlin Capital Advisors organised the meeting, with Fintrekk Capital, Alpha AMC, Street Smart Ventures, Minerva Capital, Swaraj Holdings, Green Portfolio and PinpointX Capital listed as participants. The company said no unpublished price-sensitive information would be shared. Sat Kartar's Delhi hospital was a 30-bed unit, while the wider company sold Ayurveda products through its own and third-party e-commerce channels.

Powered by Tijori

Aug 5 (Reuters) - Sat Kartar Life Ltd STKA.NS:

• SAT KARTAR LIFE - TO ESTABLISH HOSPITAL-CUM-THERAPY CENTRE IN GURUGRAM FOR 10 MILLION RUPEES

Source text: ID:nNSE3xh9g3

Further company coverage: STKA.NS

(([email protected];))

May 5 (Reuters) - Sat Kartar Life Ltd STKA.NS:

• SAT KARTAR LIFE LTD MARCH-QUARTER CONSOL PROFIT 98 MILLION RUPEES

• SAT KARTAR LIFE LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.11 BILLION RUPEES

Source text: [ID:]

Further company coverage: STKA.NS

(([email protected];))

March 5 (Reuters) - Sat Kartar Life Ltd STKA.NS:

• COMMENCES OPERATIONS OF SAT KARTAR SANJEEVAN HOSPITAL IN DELHI

Source text: ID:nNSE5bg1Nj

Further company coverage: STKA.NS

(([email protected];;))

Feb 7 (Reuters) - Sat Kartar Shopping Ltd STKA.NS:

• APPROVES 3 MILLION RUPEES INVESTMENT IN PLANTOMED NEUTRACEUTICALS

Source text: ID:nNSE9zQHTv

Further company coverage: STKA.NS

(([email protected];;))